Clinical trials: Antipsychotic
Hyperglycemia, Hyperlipidemia
Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone
Primary Aim: To test the acute effects of olanzapine or ziprasidone administration, in comparison to placebo, on insulin sensitivity in antipsychotic-naïve healthy young men, measured as whole-body dextrose infusion rates…
- Trial name
- NCT00910988
- Testing
- Olanzapine, Ziprasidone
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Neuroleptic-induced Tardive Dyskinesia
Sarizotan in the Treatment of Neuroleptic-induced Tardive Dyskinesia
TD is a troublesome and potentially irreversible side effect associated with the use of neuroleptics. While the newer neuroleptics are improved in this regard, they all still carry the risk of TD.
- Trial name
- NCT00310661
- Testing
- Sarizotan
- Where
- 2 sites in Canada, India
- Volunteers
- 60 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Schizoaffective
Do Self-Report and Physician Impressions of Adherence to Oral Antipsychotic Medication Agree With Objective Data?
The purpose of this study is to prospectively examine adherence to oral atypical antipsychotics in patients with schizophrenia. We are psrticularly interested in examining the level of agreement among self-report, physician…
- Trial name
- NCT00223522
- Testing
- MEMS caps
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Schizophrenia
A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia
The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with chronic phase or elderly schizophrenia.
- Trial name
- NCT01625897
- Testing
- MP-214, Risperidone
- Where
- Japan
- Volunteers
- 125 people
- Sponsor
- Tanabe Pharma Corporation
Schizophrenia, Psychotic Disorders
A Comparison of the Effectiveness and Safety of Injectable Risperidone With That of Risperidone Tablets in the Treatment of Patients With Chronic Schizophrenia
The primary purpose of the study is to show that treatment with an injectable formulation of risperidone is not less effective than and has a similar safety profile to risperidone tablets in patients with chronic schizophrenia.
- Trial name
- NCT00249223
- Testing
- Risperidone Long acting injectable
- Volunteers
- 641 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Schizophrenia
Effectiveness of Atypical Antipsychotics on Anhedonic Features in Patients With Schizophrenia
This prospective, multi-center, 12 weeks naturalistic NIS trial will be conducted in 25 hospitals in naturalistic treatment setting.
- Trial name
- PLEASURE (NCT01160679)
- Where
- 12 sites in South Korea
- Volunteers
- 231 people
- Sponsor
- AstraZeneca
Schizophrenia, Schizoaffective Disorder
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
To test the feasibility of studying effects of smoking cessation with varenicline on antipsychotic drug-induced neurological side effects, we propose a 12 week pilot study of smoking cessation treatment with varenicline in 10…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Tobacco Smoking, Tardive Dyskinesia
- Trial name
- NCT03495024
- Testing
- Varenicline
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Corporal Michael J. Crescenz VA Medical Center
Schizophrenia, Schizoaffective Disorder
Validity of the Spanish Version of Subjective Well-being Under Neuroleptics Scale (SWN-K) in Patients With Schizophrenia
Observational, short-term prospective, multicenter study to assess psychometric properties of the Spanish version of SWN-K scale in patients with schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- SWN-K (NCT00749970)
- Where
- 14 sites in Spain
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Schizophrenia
Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia
This study is being conducted to find a way to predict how individual schizophrenic patients will respond if they are treated with different types of antipsychotic drugs.
- Trial name
- BEST (NCT00712270)
- Testing
- Aripiprazole, Risperidone
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Kettering Health Network
Schizophrenia
Antipsychotic Effects of Probiotics and Prebiotics on Patients With Schizophrenia
In this study, investigators will evaluate the efficacy and related mechanism of probiotics and prebiotics as an add-on treatment in improving the antipsychotic induced psychotic syndrome, the cognitive impairment…
- Trial name
- NCT04291469
- Testing
- Probiotics（Live combined bifidobacteria, lactobacillus and maltodextrin tables), Prebiotics (Combined inulin and maltodextrin tables), maltodextrin
- Where
- China
- Volunteers
- 200 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Schizophrenia
Amantadine as Adjunctive Therapy to Antipsychotics in Schizophrenia
Amantadine as add-on therapy to antipsychotics may improve schizophrenia positive, negative and cognitive symptoms.
- Trial name
- NCT00999505
- Testing
- Amantadine
- Where
- Brazil
- Volunteers
- 40 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Schizophrenia
Long-Term Study of MP-214 in Patients With Schizophrenia
The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with schizophrenia.
- Trial name
- NCT01626872
- Testing
- MP-214 3mg, MP-214 6mg, MP-214 9mg
- Where
- 3 sites in Japan, South Korea and 1 more
- Volunteers
- 254 people
- Sponsor
- Tanabe Pharma Corporation
Volunteers on Chronic, Stable Antipsychotic Regimens
Staccato Loxapine Multidose PK
The objectives of this trial are to assess the safety, tolerability, and pharmacokinetics of multiple inhaled doses of Staccato Loxapine.
- Trial name
- NCT00555412
- Testing
- A - 10 mg loxapine q 4 h x 3 (30 mg total), B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total), C - 5 mg loxapine q 4 h x 3 (15 mg total)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Alexza Pharmaceuticals, Inc.
Schizophrenia, Schizoaffective Disorder
An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
The aim of this study is to evaluate the effectiveness, safety, and tolerability of metformin treatment in children and adolescents suffering from weight gain secondary to use of atypical antipsychotic medications.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar Disorder
- Trial name
- NCT00391261
- Testing
- Metformin
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Cambridge Health Alliance
Schizophrenia
Treatment of Patients With Recently Exacerbated Schizophrenia With Paliperidone Palmitate
The purpose of this study is to explore the efficacy of paliperidone palmitate administered as a once monthly injection in patients with an acute exacerbation of schizophrenia.
- Trial name
- NCT01448720
- Testing
- Paliperidone palmitate
- Where
- 12 sites in Brazil, Colombia and 1 more
- Volunteers
- 142 people
- Sponsor
- Janssen-Cilag Farmaceutica Ltda.
Antipsychotic-induced Weight Gain
The Effect of CORT118335 on Olanzapine-Induced Weight Gain
This study will investigate if there is any difference in the amount of weight gained by participants taking olanzapine with CORT118335 compared with olanzapine with placebo (a dummy test medicine which looks like CORT118335 but…
- Trial name
- NCT03877562
- Testing
- Olanzapine, CORT118335
- Where
- United Kingdom
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Corcept Therapeutics
Schizoaffective Disorder, Psychotic Disorder
Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.
The purpose of this study is to measure the effectiveness and assess the safety of two dosages of the antipsychotic paliperidone extended-release (ER) in patients who are experiencing an acute episode of schizoaffective disorder.
- Trial name
- NCT00397033
- Testing
- Paliperidone ER
- Volunteers
- 316 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Effects of Hyperprolactinemia Induced by Antipsychotic Drugs on Bone Metabolism
The study is aimed to assess the severities of hyperprolactinemia caused by antipsychotic drugs and the effects of the duration of hyperprolactinemia on bone metabolism in schizophrenia patients.
- Trial name
- NCT03675750
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Shanghai Mental Health Center
Schizophrenia, Schizophrenia Relapse
10-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals
This open-label, non-randomized, prospective study will evaluate the risk of symptoms recurrence during the ten years after antipsychotic discontinuation in a sample of functionally recovered first-episode patients with…
- Conditions
- Schizophrenia, Schizophrenia Relapse, Schizophrenia Spectrum and Other Psychotic Disorders
- Trial name
- ADARFEP_10Y (NCT03090490)
- Testing
- Antipsychotic treatment discontinuation, Maintenance treatment discontinuation
- Where
- Spain
- Volunteers
- 68 people
- Sponsor
- Fundación Marques de Valdecilla
Schizophrenia
A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia
This Phase 3, multi-center, randomized, double blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 (bitopertin) in participants with persistent, predominant negative symptoms of…
- Trial name
- NCT01192880
- Testing
- Bitopertin, Antipsychotics
- Where
- 103 sites in United States, Bulgaria and 5 more
- Volunteers
- 625 people
- Sponsor
- Hoffmann-La Roche